Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11122135rdf:typepubmed:Citationlld:pubmed
pubmed-article:11122135lifeskim:mentionsumls-concept:C1527169lld:lifeskim
pubmed-article:11122135lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:11122135lifeskim:mentionsumls-concept:C0013018lld:lifeskim
pubmed-article:11122135lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:11122135lifeskim:mentionsumls-concept:C0079459lld:lifeskim
pubmed-article:11122135lifeskim:mentionsumls-concept:C0210630lld:lifeskim
pubmed-article:11122135lifeskim:mentionsumls-concept:C0040739lld:lifeskim
pubmed-article:11122135lifeskim:mentionsumls-concept:C0585361lld:lifeskim
pubmed-article:11122135lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:11122135lifeskim:mentionsumls-concept:C0524864lld:lifeskim
pubmed-article:11122135pubmed:issue3lld:pubmed
pubmed-article:11122135pubmed:dateCreated2001-1-26lld:pubmed
pubmed-article:11122135pubmed:abstractTextTo evaluate the schedule dependency of granulocyte colony-stimulating factor (G-CSF) (filgrastim) for stem cell mobilization, we conducted a randomized comparison in 50 healthy donors, with one subcutaneous daily injection of 10 microg/kg G-CSF (n = 25) compared with twice injections daily of 5 microg/kg G-CSF (n = 25). The two groups were well balanced for age, body weight and sex. G-CSF application was performed on an out-patient basis and leukapheresis was started in all donors on day 5. The most frequent side-effects of G-CSF were mild to moderate bone pain (88%), mild headache (72%), mild fatigue (48-60%) and nausea (8%) without differences between the two groups. The CD34(+) cell count in the first apheresis was 5.4 x 10(6)/kg donor weight (range 2.8-13.3) in the 2 x 5 microg/kg group compared with 4.0 x 10(6)/kg (range 0.4-8.8) in the 1 x 10 microg/kg group (P = 0.007). The target of collecting > 3.0 x 10(6) CD34(+) cells/kg donor weight with one apheresis procedure was achieved in 24/25 (96%) donors in the 2 x 5 microg/kg group and in 17/25 (68%) donors in the 1 x 10 microg/kg group. The target of collecting > 5.0 x 10(6) CD34(+) cells/kg in the first apheresis was achieved in 64% in the 2 x 5 microg/kg group, but in only 36% in the 1 x 10 microg/kg group. The progenitor cell assay for granulocyte-macrophage colony-forming units (CFU-GM) and erythroid burst-forming units (BFU-E) was higher in the 2 x 5 microg/kg group than in the 1 x 10 microg/kg group (7.0 vs. 3.5 x 10(5)/kg, P = 0.01; 6.6 vs. 5.0 x 10(5)/kg; P = 0.1). Administering G-CSF (filgrastim) at a dosage of 5 microg/kg twice daily rather than 10 microg/kg once daily is recommended; this leads to a higher CD34(+) cell yield and requires fewer apheresis procedures without increasing toxicity or cost.lld:pubmed
pubmed-article:11122135pubmed:languageenglld:pubmed
pubmed-article:11122135pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11122135pubmed:citationSubsetIMlld:pubmed
pubmed-article:11122135pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11122135pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11122135pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11122135pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11122135pubmed:statusMEDLINElld:pubmed
pubmed-article:11122135pubmed:monthDeclld:pubmed
pubmed-article:11122135pubmed:issn0007-1048lld:pubmed
pubmed-article:11122135pubmed:authorpubmed-author:KrügerWWlld:pubmed
pubmed-article:11122135pubmed:authorpubmed-author:ZanderA RARlld:pubmed
pubmed-article:11122135pubmed:authorpubmed-author:GutensohnKKlld:pubmed
pubmed-article:11122135pubmed:authorpubmed-author:LöligerCClld:pubmed
pubmed-article:11122135pubmed:authorpubmed-author:KrögerNNlld:pubmed
pubmed-article:11122135pubmed:authorpubmed-author:CortesLLlld:pubmed
pubmed-article:11122135pubmed:authorpubmed-author:CarreroIIlld:pubmed
pubmed-article:11122135pubmed:authorpubmed-author:RengeiBBlld:pubmed
pubmed-article:11122135pubmed:issnTypePrintlld:pubmed
pubmed-article:11122135pubmed:volume111lld:pubmed
pubmed-article:11122135pubmed:ownerNLMlld:pubmed
pubmed-article:11122135pubmed:authorsCompleteYlld:pubmed
pubmed-article:11122135pubmed:pagination761-5lld:pubmed
pubmed-article:11122135pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:11122135pubmed:meshHeadingpubmed-meshheading:11122135...lld:pubmed
pubmed-article:11122135pubmed:meshHeadingpubmed-meshheading:11122135...lld:pubmed
pubmed-article:11122135pubmed:meshHeadingpubmed-meshheading:11122135...lld:pubmed
pubmed-article:11122135pubmed:meshHeadingpubmed-meshheading:11122135...lld:pubmed
pubmed-article:11122135pubmed:meshHeadingpubmed-meshheading:11122135...lld:pubmed
pubmed-article:11122135pubmed:meshHeadingpubmed-meshheading:11122135...lld:pubmed
pubmed-article:11122135pubmed:meshHeadingpubmed-meshheading:11122135...lld:pubmed
pubmed-article:11122135pubmed:meshHeadingpubmed-meshheading:11122135...lld:pubmed
pubmed-article:11122135pubmed:meshHeadingpubmed-meshheading:11122135...lld:pubmed
pubmed-article:11122135pubmed:meshHeadingpubmed-meshheading:11122135...lld:pubmed
pubmed-article:11122135pubmed:meshHeadingpubmed-meshheading:11122135...lld:pubmed
pubmed-article:11122135pubmed:meshHeadingpubmed-meshheading:11122135...lld:pubmed
pubmed-article:11122135pubmed:meshHeadingpubmed-meshheading:11122135...lld:pubmed
pubmed-article:11122135pubmed:meshHeadingpubmed-meshheading:11122135...lld:pubmed
pubmed-article:11122135pubmed:meshHeadingpubmed-meshheading:11122135...lld:pubmed
pubmed-article:11122135pubmed:year2000lld:pubmed
pubmed-article:11122135pubmed:articleTitleA randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation.lld:pubmed
pubmed-article:11122135pubmed:affiliationDepartment of Bone Marrow Transplantation, University of Hamburg, Germany. nkroeger@uke.uni-hamburg.delld:pubmed
pubmed-article:11122135pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11122135pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:11122135pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:11122135pubmed:publicationTypeRandomized Controlled Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11122135lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11122135lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11122135lld:pubmed